SAB Biotherapeutics, Inc.
SABS
$1.79
$0.03992.28%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -40.94% | -63.06% | -56.68% | -79.48% | -90.63% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -40.94% | -63.06% | -56.68% | -79.48% | -90.63% |
| Cost of Revenue | 84.38% | 39.99% | 2.63% | -27.11% | -54.63% |
| Gross Profit | -104.04% | -67.64% | -26.02% | -17.37% | -14.25% |
| SG&A Expenses | -42.09% | 121.95% | 90.47% | 67.14% | 44.92% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 9.72% | 71.03% | 35.05% | 5.61% | -23.68% |
| Operating Income | -12.70% | -91.33% | -54.98% | -42.05% | -31.67% |
| Income Before Tax | 19.17% | -67.61% | -38.27% | -46.85% | -125.45% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 19.17% | -67.46% | -38.15% | -47.21% | -125.14% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 19.17% | -67.46% | -38.15% | -47.21% | -125.14% |
| EBIT | -12.70% | -91.33% | -54.98% | -42.05% | -31.67% |
| EBITDA | -10.99% | -100.20% | -57.36% | -42.65% | -33.69% |
| EPS Basic | 48.73% | -5.16% | 8.50% | -4.99% | -67.82% |
| Normalized Basic EPS | 48.69% | -5.07% | 8.57% | -4.53% | -67.62% |
| EPS Diluted | 48.73% | -5.16% | 8.50% | -4.99% | -66.70% |
| Normalized Diluted EPS | 48.69% | -5.07% | 8.57% | -4.53% | -67.05% |
| Average Basic Shares Outstanding | 67.76% | 74.15% | 61.52% | 44.90% | 26.83% |
| Average Diluted Shares Outstanding | 67.76% | 74.15% | 61.52% | 44.90% | 24.89% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |